Sam Altman on OpenAI's closed-source approach

Sam Altman, the CEO of OpenAI, is backing a groundbreaking initiative aimed at extending human lifespan by a decade through ...
Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...
Disease-reversal startup Retro Biosciences is aiming for a $1 billion funding round, a spokesperson for the company confirmed ...
"Cut your expectations by 100x," says Sam Altman, who also recently predicted superintelligence was just "a few thousand days ...